San Diego, California, April 9, 2024 – HKeybio, the "Autoimmune Disease Model Expert" and a leading preclinical CRO exclusively focused on autoimmune and allergic diseases, officially announces its participation in the 2024 BIO International Convention & Exhibition. Held from June 3rd to 6th at the San Diego Convention Center, this premier biotechnology event will bring together over 18,000 industry leaders, researchers and investors from more than 65 countries. HKeybio will showcase its comprehensive portfolio of validated animal models and end-to-end in vivo efficacy services to explore strategic collaborations with global pharmaceutical and biotech partners.

The 2024 BIO International Convention serves as the most influential gathering for the global biotechnology industry, providing a unique platform for companies to showcase innovations, forge partnerships and advance drug development. For the autoimmune disease sector, which affects over 23.5 million people in the United States alone, this year's event is particularly significant as it features dedicated tracks on preclinical research, translational medicine and novel immunotherapies.

With the global autoimmune disease drug market projected to grow steadily in the coming years, there is an urgent need for more reliable preclinical tools to address the high clinical failure rate of drug candidates. BIO 2024 will host over 300 scientific sessions addressing key challenges in autoimmune drug development, including model validation, efficacy testing and regulatory compliance, making it an ideal venue for HKeybio to share its specialized expertise.

HKeybio has established itself as a trusted global partner for autoimmune drug development, with a core technical team possessing over 20 years of comprehensive experience in the entire autoimmune drug R&D chain. The company has obtained ISO9001 quality system certification, ensuring consistent and high-quality research services.

Headquartered in Suzhou Industrial Park, China, HKeybio operates a full-chain experimental base covering molecular biology, cell testing, pathology analysis, small animal research and analytical detection. It also runs two dedicated non-human primate (NHP) research bases in Suzhou and Guangxi, enabling large-scale and standardized preclinical studies. With nearly 60 employees, all project leaders hold master's or doctoral degrees, bringing deep scientific expertise to every project.

HKeybio's core capabilities include:

A key differentiator for HKeybio is its extensive experience supporting IND submissions. The team has accumulated over 300 successful IND filing experiences for autoimmune diseases, enabling it to efficiently address various challenges in the drug development and regulatory approval process. This proven track record has made HKeybio a preferred partner for pharmaceutical companies looking to accelerate their preclinical programs.

"We are excited to participate in BIO 2024 and connect with global partners who share our commitment to advancing autoimmune disease treatments," said Dr. Zhao, CEO of HKeybio. "Our specialized focus on autoimmune and allergic diseases, combined with our comprehensive model resources and regulatory expertise, allows us to deliver high-quality preclinical data that supports successful IND submissions."

During the convention, HKeybio's team of scientific experts will be available at its booth to discuss custom research solutions, share insights into autoimmune disease model development and explore potential collaborations. For more information about HKeybio or to schedule a meeting at BIO 2024, please visit www.hkeybio.com or contact tech@hkeybio.com.